OrbiMed Advisors LLC's Form 4 filing
Kinnate Biopharma Inc. (KNTE) · filed May 8, 2023
- Accession no.
- 0000947871-23-000541
- Filed
- May 8, 2023, 5:22 PM ET
- Trade date
- May 4-5, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions. Open-market purchases total $4.09M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| OrbiMed Advisors LLCCIK 0001055951 | Director, 10% Owner |
| OrbiMed Capital LLCCIK 0001157524 | Director, 10% Owner |
| OrbiMed Capital GP VII LLCCIK 0001760648 | Director, 10% Owner |
| OrbiMed Genesis GP LLCCIK 0001808744 | Director, 10% Owner |
| OrbiMed Capital GP VIII LLCCIK 0001845804 | Director, 10% Owner |
| OrbiMed Advisors IV LtdCIK 0001966835 | Director, 10% Owner |
| OrbiMed Asia GP IV, L.P.CIK 0001966836 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 4, 2023 | Common Stock | PPurchaseAcquired | +83,459 | $2.75F1 | +$229,512.25 | 877,827 | Indirect | Duplicate filing |
| May 4, 2023 | Common Stock | PPurchaseAcquired | +312,991 | $2.75F1 | +$860,725.25 | 4,738,453 | Indirect | Duplicate filing |
| May 4, 2023 | Common Stock | PPurchaseAcquired | +83,459 | $2.75F1 | +$229,512.25 | 877,827 | Indirect | Duplicate filing |
| May 5, 2023 | Common Stock | PPurchaseAcquired | +490,512 | $2.82F2 | +$1,383,243.84 | 1,368,339 | Indirect | Duplicate filing |
| May 5, 2023 | Common Stock | PPurchaseAcquired | +490,511 | $2.82F2 | +$1,383,241.02 | 1,368,338 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.75 to a high of $2.86 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
Referenced by the price of 3 transactions in Table I.
- F2
Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.80 to a high of $2.89 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.
Referenced by the price of 2 transactions in Table I.